AF identification in individuals with prior hyperlipidaemia prompted a change in management for 17: (re-)introduction of lipid-lowering therapy, initially statin (n=13), supplemented with ezetimibe (n=1), or statin replaced by a PCSK9 inhibitor together with ezetimibe (n=1), or increased dose (n=2). Here, PCSK9 is linked to hyperlipidemia.